- Executive Summary
- Research Scope
- Research Methodology
- Key Findings
- Drug Discovery and Development A Sneak Preview
- Drug Discovery and Development Process
- Development Cycle Times
- Business Models and Participants
- Business Model Evolution
- Strategic Assessment of the Industry Environment
- Drug Discovery and Development Focus
- Global Expenditures
- Manufacturing and Commercialization
- Benchmarking Model and Assumptions
- R&D Benchmarking: Framework
- R&D Benchmarking: Main Strengths by Company
- R&D Benchmarking: Key Takeaways
- Case Representative Studies: AbbVie - Amgen - Bayer - Roche
- Competitor Landscape
- Core Therapeutic Areas
- Principal Facts
- Pharmacology Process
- Pipeline
- Intellectual Property
- Income Statement: Explanatory Comments
- Income Statement: Costs and Expenses
- Research and Development
- Emerging Markets
- Partnerships and Acquisitions
- Competitor Landscape
- Core Therapeutic Areas
- Principal Facts
- Pipeline
- Income Statement: Costs and Expenses
- Research and Development
- Big Pharma Strategy Assessment
- Discovery Research Model
- Strategic Roadmap
- Key Insights
- Competitor Landscape
- Core Therapeutic Areas
- Principal Facts
- Pipeline
- Pharmacology Process
- Income Statement: Costs and Expenses
- Research and Development
- Emerging Markets
- Competitor Landscape
- Core Therapeutic Areas
- Principal Facts
- Pipeline
- Pharmacology Process
- Income Statement: Costs and Expenses
- Research and Development
- Innovation Model
- Emerging Markets
- Partnerships
Evolving Technology Platforms in Pharma-Biotech
The continued development of new treatments associated with the demographic trends and public health considerations is essential. The biopharmaceutical industry is one of the most research intensive sectors in developed nations. Investments are more than USD 125 billion, especially in early stages development phases, including the processes of discovering and developing new medicines. Biopharmaceutical innovation has played a major role in the improvement of both length and quality of life during the past decade, considerably reducing the disease burden for individuals and the society. Groundbreaking advances in the scientific understanding of the underlying mechanisms of disease are paving the way for precision medicine for the upcoming years. Indeed, the promise of personalized medicine is becoming a reality generating notable improvements in human health and the potential to reduce the socioeconomic burden of disease. This research service (RS) depicts the current landscape of biopharmaceutical development, focusing on medicines that have progressed beyond early stage development and have recently entered clinical testing in human volunteers or first-in-human studies. The RS also includes:
R&D portfolio and budgetary analysis
Environmental analysis, depicting the key technical challenges, key business challenges, and emerging market needs
Industry best practices and strategic insights, measuring performance, assessment of partnerships and alliances and R&D pipeline by milestones
Strategic evaluation of R&D portfolio
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBookOther tasks
;